| Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial AM Jastreboff, LM Kaplan, JP Frías, Q Wu, Y Du, S Gurbuz, T Coskun, ... New England Journal of Medicine 389 (6), 514-526, 2023 | 203 | 2023 |
| Development of a claims-based frailty indicator anchored to a well-established frailty phenotype JB Segal, HY Chang, Y Du, JD Walston, MC Carlson, R Varadhan Medical care 55 (7), 716-722, 2017 | 188 | 2017 |
| Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open … J Guinney, T Wang, TD Laajala, KK Winner, JC Bare, EC Neto, SA Khan, ... The Lancet Oncology 18 (1), 132-142, 2017 | 161 | 2017 |
| LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept T Coskun, S Urva, WC Roell, H Qu, C Loghin, JS Moyers, LS O’Farrell, ... Cell metabolism 34 (9), 1234-1247. e9, 2022 | 97 | 2022 |
| LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised … S Urva, T Coskun, MT Loh, Y Du, MK Thomas, S Gurbuz, A Haupt, ... The Lancet 400 (10366), 1869-1881, 2022 | 91 | 2022 |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 … J Rosenstock, J Frias, AM Jastreboff, Y Du, J Lou, S Gurbuz, MK Thomas, ... The Lancet 402 (10401), 529-544, 2023 | 89 | 2023 |
| Multiple testing procedures for adaptive enrichment designs: combining group sequential and reallocation approaches M Rosenblum, T Qian, Y Du, H Qiu, A Fisher Biostatistics, kxw014, 2016 | 30 | 2016 |
| Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist O Benichou, T Coskun, MD Gonciarz, P Garhyan, AC Adams, Y Du, ... Cell metabolism 35 (2), 274-286. e10, 2023 | 27 | 2023 |
| SQUAREM: An R package for off-the-shelf acceleration of EM, MM and other EM-like monotone algorithms Y Du, R Varadhan Journal of Statistical Software 92 (7), 1-41, 2020 | 20 | 2020 |
| Deep personalized glucose level forecasting using attention-based recurrent neural networks M Armandpour, B Kidd, Y Du, JZ Huang 2021 International Joint Conference on Neural Networks (IJCNN), 1-8, 2021 | 15 | 2021 |
| An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles Y Du, J Yin, DJ Sargent, SJ Mandrekar Journal of Biopharmaceutical Statistics, 2018 | 13 | 2018 |
| The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying S Urva, L O'Farrell, Y Du, MT Loh, A Hemmingway, H Qu, ... Diabetes, Obesity and Metabolism, 2023 | 7 | 2023 |
| Lasso estimation of hierarchical interactions for analyzing heterogeneity of treatment effect Y Du, H Chen, R Varadhan Statistics in Medicine 40 (25), 5417-5433, 2021 | 7 | 2021 |
| 333-OR: oxyntomodulin analog LY3305677 (LY) improves glycemic control and weight loss in healthy volunteers and subjects with type 2 diabetes (T2D) C Benson, LS Tham, YU Du, S Gurbuz, DA Robins, KJ Mather, CC Tang, ... Diabetes 71 (Supplement_1), 2022 | 6 | 2022 |
| Triple hormone receptor agonist retatrutide resolves steatosis in> 85% of subjects with MASLD and obesity in association with improved metabolic health A Sanyal, JP Frias, MK Thomas, KJ Mather, Q Wu, Y Du, B Brouwers, ... Hepatology 78, S154-S155, 2023 | 4 | 2023 |
| 104-OR: novel GIP/GLP-1/glucagon receptor agonist LY3437943: a first-in-human dose study in healthy subjects S Urva, YU Du, MK Thomas, Z Milicevic, T Coskun, C Benson, C Loghin Diabetes 70 (Supplement_1), 2021 | 4 | 2021 |
| A General Form of Covariate Adjustment in Randomized Clinical Trials MS Bannick, J Shao, J Liu, Y Du, Y Yi, T Ye arXiv preprint arXiv:2306.10213, 2023 | 3 | 2023 |
| 340-OR: LY3437943 (LY), a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment S URVA, MEIT LOH, T COSKUN, YU DU, C BENSON, C LOGHIN, ... Diabetes 71 (Supplement_1), 2022 | 3 | 2022 |
| Understanding and adjusting for the selection bias from a proof‐of‐concept study to a more confirmatory study Y Qu, Y Du, Y Zhang, L Shen Statistics in Medicine 39 (30), 4593-4604, 2020 | 3 | 2020 |
| Phase II Adaptive Enrichment Design to Determine the Population to Enroll in Phase III Trials, by Selecting Thresholds for Baseline Disease Severity Y Du, GL Rosner, M Rosenblum bepress, 2018 | 3 | 2018 |
